Notice for decitabine and cedazuridine (Otsuka Australia Pharmaceuticals Pty Ltd)
Active ingredients
decitabine and cedazuridine
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Film-coated tablet
Indication
Treatment of adult patients with MDS intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups, and patients with chronic myelomonocytic leukemia (CMML).
Therapeutic area
Haematology